PCI Biotech: European patent for treatment of bile duct cancer with the fimaChem technology
16 nov. 2020 02h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 16 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the European Patent Office (EPO) has informed the company that a new...
PCI Biotech third quarter 2020 results
11 nov. 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 11 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2020 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to third quarter 2020 results presentation
04 nov. 2020 03h15 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 4 November 2020 - PCI Biotech’s (OSE: PCIB) third quarter 2020 interim report will be released on 11 November 2020 at 07.00 CET. The interim report and presentation will be made...
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
26 oct. 2020 07h48 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Preclinical research collaboration with big pharma ended
21 oct. 2020 02h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 21 October 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today informed that AstraZeneca has elected not to enter into a definitive agreement for the...
PCI Biotech: Employee share option scheme
06 oct. 2020 09h02 HE
|
PCI Biotech Holding ASA
Oslo, 06 October 2020 In accordance with the authorisation granted by the Annual General Meeting 27 May 2020, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 540,000 share...
PCI Biotech: Capital increase registered and listing of new shares
08 sept. 2020 06h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 8 September 2020. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 60,500 new shares following...
PCI Biotech: Exercise of employee share options, mandatory notification of trade and resolution to increase share capital
02 sept. 2020 12h14 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 2 September 2020 – Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the “Company”). 1. ...
PCI Biotech announce a research collaboration with DCprime to explore novel cancer vaccination concepts
01 sept. 2020 03h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 1 September 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation and DCprime, the...
PCI Biotech: First half-year 2020 results
26 août 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year and Q2 2020 results. Please find enclosed the report...